Mitral regurgitation (MR) is the most common valvular disease. With a rising incidence in older age, the prevalence of relevant comorbidities inevitably increases. Considering the constantly aging population with high surgical risk, transcatheter therapy of MR is gaining increasing importance. Interventional therapy of either primary or secondary MR represents an alternative to pure drug or surgical therapy. With mitral valve transcatheter edge-to-edge repair, a well-established treatment has evolved in the past two decades. In addition, direct or indirect annuloplasty and ultimately transcatheter mitral valve implantation further expand the armamentarium. The current broad spectrum of interventional therapy options allows for patient-oriented therapy individually targeting different MR pathologies. This review discusses the current landscape of transcatheter therapies for relevant MR.

二尖瓣关闭不全 (MR) 是最常见的瓣膜疾病。随着老年发病率的上升，相关合并症的患病率不可避免地增加。考虑到不断老龄化的高手术风险人群，MR 的经导管治疗变得越来越重要。原发性或继发性 MR 的介入治疗代表了纯药物或手术治疗的替代方案。随着二尖瓣经导管边缘到边缘修复，在过去的二十年中已经发展了一种完善的治疗方法。此外，直接或间接瓣环成形术和最终经导管二尖瓣植入术进一步扩大了医疗设备。当前广泛的介入治疗选项允许针对不同的 MR 病理分别进行以患者为导向的治疗。